PRPH

MKT CAP:$539545

ProPhase Labs, Inc.

Market Cap

$539545

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$0.13-$0.23 (-65.00%)

Apr 24, 2026

Company Details

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segmen...

CEO

Ted William Karkus

IPO Date

Apr 4, 1994

Website

www.prophaselabs.com

Key Metrics TTM

Revenue

$24M

-39.3% YoY

Net Income

-$20M

EPS (Diluted)

-$7.70

Free Cash Flow

-$31M

Revenue / Share

$5.71

Gross Margin

39.6%

Operating Margin

-83.5%

Net Margin

-83.9%

FCF Margin

-130.0%

P/S

0.0x

P/E

—

Earnings Reports

Q3 2025

Nov 19, 2025

$883.0KEPS -$1.60

Q2 2025

Aug 13, 2025

$1MEPS -$1.10

Q3 2023

Nov 13, 2023

$8MEPS -$3.00

Q2 2023

Aug 11, 2023

$13MEPS -$2.00

Q3 2021

Nov 12, 2021

$9M+146.7%EPS -$2.60

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 18	$4M	$1M	-$406.0K
Q1 19	$2M	$520.0K	-$1M
Q2 19	$2M	$261.0K	-$1M
Q3 19	$3M	$834.0K	-$461.0K
Q4 19	$3M	$1M	-$466.0K
Q1 20	$2M	$415.0K	-$812.0K
Q2 20	$4M	$1M	$59.0K
Q3 20	$4M	$1M	-$567.0K
Q4 20	$5M	$2M	-$773.0K
Q1 21	$15M	$9M	$1M
Q2 21	$9M	$4M	-$1M
Q3 21	$9M	$4M	-$4M
Q2 23	$13M	$6M	-$5M
Q3 23	$8M	$2M	-$6M
Q2 25	$1M	$734.0K	-$4M
Q3 25	$883.0K	-$123.0K	-$5M

Valuation

Quarter	P/S	P/E
Q4 18	55.5x	—
Q1 19	56.5x	—
Q2 19	48.5x	—
Q3 19	41.3x	—
Q4 19	47.8x	—
Q1 20	46.5x	—
Q2 20	28.8x	—
Q3 20	17.7x	—
Q4 20	43.9x	—
Q1 21	16.2x	—
Q2 21	15.2x	—
Q3 21	10.2x	—
Q2 23	13.2x	—
Q3 23	9.8x	—
Q2 25	5.0x	—
Q3 25	7.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	$4M	$4M
Q3 21	-$6M	-$6M
Q4 21	-$5M	-$389.0K
Q1 22	$20M	$19M
Q2 22	$5M	$4M
Q3 22	$3M	$2M
Q4 22	$811.0K	-$785.0K
Q1 23	$476.0K	-$41.0K
Q2 23	-$7M	-$8M
Q3 23	-$5M	-$5M
Q4 23	-$213.0K	-$2M
Q1 24	-$5M	-$6M
Q2 24	-$5M	-$5M
Q3 24	-$4M	-$4M
Q2 25	-$247.0K	-$247.0K
Q3 25	-$22M	-$22M

Capital Expenditures

Quarter	CapEx
Q2 21	$310.0K
Q3 21	$21.0K
Q4 21	$4M
Q1 22	$1M
Q2 22	$674.0K
Q3 22	$554.0K
Q4 22	$2M
Q1 23	$517.0K
Q2 23	$660.0K
Q3 23	$668.0K
Q4 23	$1M
Q1 24	$939.0K
Q2 24	$26.0K
Q3 24	$176.0K
Q2 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 18	-1.4%	+0.4%
Q1 19	-32.0%	-0.1%
Q2 19	-48.2%	-15.3%
Q3 19	+13.4%	-3.7%
Q4 19	-23.3%	-19.8%
Q1 20	-18.6%	-19.7%
Q2 20	+119.4%	+22.1%
Q3 20	+38.8%	+36.6%
Q4 20	+64.4%	+64.6%
Q1 21	+708.8%	+420.4%
Q2 21	+152.3%	+197.2%
Q3 21	+146.7%	+197.7%
Q2 23	+156.0%	+201.1%
Q3 23	-45.2%	+5.6%
Q2 25	-86.4%	-51.5%
Q3 25	-90.7%	-57.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$1M	11.8%
Q3 21	$934.0K	9.9%
Q4 21	$745.0K	—
Q1 22	$482.0K	—
Q2 22	$528.0K	—
Q3 22	$2M	—
Q4 22	$1M	—
Q1 23	$947.0K	—
Q2 23	$1M	8.0%
Q3 23	$857.0K	10.2%
Q4 23	$676.0K	—
Q1 24	$2M	—
Q2 24	$796.0K	—
Q3 24	$636.0K	—
Q2 25	$508.0K	40.7%
Q3 25	$431.0K	48.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 18	$79.0K	$1M	$305.0K	—
Q1 19	$94.0K	$1M	$266.0K	—
Q2 19	$95.0K	$1M	$342.0K	—
Q3 19	$57.0K	$936.0K	$302.0K	—
Q4 19	$86.0K	$1M	$132.0K	—
Q1 20	$59.0K	$998.0K	$170.0K	—
Q2 20	$65.0K	$1M	$125.0K	—
Q3 20	$57.0K	$1M	$253.0K	—
Q4 20	$452.0K	$3M	$739.0K	—
Q1 21	$115.0K	$4M	$4M	—
Q2 21	$93.0K	$5M	$830.0K	—
Q3 21	$208.0K	$6M	$1M	—
Q2 23	$572.0K	$10M	—	—
Q3 23	$428.0K	$8M	—	—
Q2 25	$4.0K	$5M	—	—
Q3 25	$6.0K	—	—	$4M

Revenue Segments

Quarter	Consumer Products	Diagnostic Services	Consumer Products Segment
Q1 21	$3M	$13M	—
Q2 21	$2M	$8M	—
Q3 21	$2M	$7M	—
Q2 23	$5M	$8M	—
Q3 23	$6M	$2M	—
Q2 25	—	—	$1M
Q3 25	—	—	$883.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 18	$3M	$18M	$22M
Q2 18	$4M	$7M	$10M
Q3 18	$2M	$7M	$9M
Q4 18	$2M	$7M	$8M
Q1 19	$2M	$4M	$7M
Q2 19	$1M	$5M	$6M
Q3 19	$968.0K	$4M	$5M
Q4 19	$434.0K	$926.0K	$1M
Q1 20	$697.0K	$840.0K	$2M
Q2 20	$3M	$3M	$6M
Q3 20	$11M	$1M	$12M
Q4 20	$7M	$2M	$8M
Q4 24	$678.0K	$0	$678.0K
Q1 25	$88.0K	$0	$88.0K
Q2 25	$169.0K	$2.0K	$171.0K
Q3 25	$405.0K	$0	$405.0K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 18	1M	+0.1%	-27.0%
Q1 19	1M	0.0%	+1.3%
Q2 19	1M	+0.0%	+1.9%
Q3 19	1M	+0.0%	+0.2%
Q4 19	1M	+0.1%	+0.2%
Q1 20	1M	0.0%	+0.2%
Q2 20	1M	+0.3%	+0.5%
Q3 20	1M	-0.1%	+0.3%
Q4 20	1M	0.0%	+0.2%
Q1 21	2M	+56.8%	+57.1%
Q2 21	2M	-16.7%	+30.4%
Q3 21	2M	+1.9%	+33.0%
Q2 23	2M	+9.1%	+45.2%
Q3 23	2M	+2.0%	-5.6%
Q2 25	4M	+141.9%	+174.1%
Q3 25	4M	0.0%	+169.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 18	$87.1K	47
Q1 19	$49.3K	47
Q2 19	$35.1K	47
Q3 19	$58.9K	47
Q4 19	$65.4K	48
Q1 20	$39.3K	48
Q2 20	$75.5K	48
Q3 20	$80.0K	48
Q4 20	$54.3K	95
Q1 21	$160.7K	95
Q2 21	$96.2K	95
Q3 21	$99.7K	95
Q2 23	$102.5K	129
Q3 23	$64.8K	129
Q2 25	$13.0K	96
Q3 25	$9.2K	96

Revenue / Employee